Roger G. Worthington P.C.   |   800.831.9399  |  Search  
   
Helping Asbestos Victims Get Justice in the Courtrooms and Help in the Hospitals since 1990.

Expand All | Contract All Empower Yourself: Free Medical/Legal Guide

-PATIENT PROFILES -California State Rock -Empower Yourself -PHLBI -Mesothelioma -Meso Causation -Meso Diagnosis -Treatment Options -Treatment Centers -Litigation -Settlements/Verdicts -Patient Advocacy -Asbestos Products -Legislative Updates -Meso Hotspots -Lung Cancer -Why You Need RGWPC -Web Links
 
 

Listen to Dr. Cameron speak about his surgery plus interferon trial
Click here

 

Free Legal and Medical Packet

Click Here
1- 800-831-9399

 

THE REAL DEAL

Meso lawyers since 1996.
First on the Internet.
First to post treatment options.

BEWARE OF FAKES

 
 

 

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
 

J Thorac Oncol. 2007 Oct;2(10):957-65. Click here to read Links

Comment in:  J Thorac Oncol. 2007 Oct;2(10):885-6.

Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V.

Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. floresr@mskcc.org

INTRODUCTION: Most studies describing the natural history and prognostic factors for malignant pleural mesothelioma antedate accurate pathologic diagnosis, staging by computed tomography, and a universal staging system. We conducted a large single-institution analysis to identify prognostic factors and assess the association of resection with outcome in a contemporary patient population.

METHODS: Patients with biopsy-proven malignant pleural mesothelioma at our institution were identified and clinical data were obtained from an institutional database. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. A p value <0.05 was considered statistically significant.

RESULTS: From 1990 to 2005, 945 patients were identified: 755 men, 190 women; median age, 66 years (range, 26-93). Extrapleural pneumonectomy was performed in 208 (22%), pleurectomy/decortication in 176 (19%). Operative mortality was 4% (16/384). Multimodality therapy including surgery was associated with a median survival of 20.1 months. Significant predictors of overall survival included histology, gender, smoking, asbestos exposure, laterality, surgical resection by extrapleural pneumonectomy or pleurectomy/decortication, American Joint Committee on Cancer stage, and symptoms. A Cox model demonstrated a hazard ratio of 1.4 without surgical resection when controlling for histology, stage, gender, asbestos exposure, smoking history, symptoms, and laterality (p = 0.003).

CONCLUSIONS: In addition to tumor histology and pathologic stage, predictors of survival include gender, asbestos exposure, smoking, symptoms, laterality, and clinical stage. Surgical resection in a multimodality setting was associated with improved survival.

 
site map   free brochure   disclaimer   800.831.9399   contact us   home